How safe is metformin when initiated in early pregnancy? A retrospective 5-year study of pregnant women with gestational diabetes mellitus from India

• Published in: Diabetes research and clinical practice Vol. 137; pp. 47 - 55
• Main Authors: Vanlalhruaii, Dasgupta, Riddhi, Ramachandran, Roshna, Mathews, Jiji E., Regi, Annie, Thomas, Niranjan, Gupta, Vijay, Visalakshi, P., Asha, H.S., Paul, Thomas, Thomas, Nihal
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.03.2018
• Subjects: SMD
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2018.01.002

•Is a safe option when compared to metformin initiated after first trimester or insulin during pregnancy.•Associated with numerically higher preterm births which warrants close monitoring.•Not associated with increase in number of stillbirths/congenital malformations/intra-uterine death. The initiation of metformin in early pregnancy in Gestational Diabetes mellitus (GDM) remains controversial. The aim of our study was to assess the influence of Metformin on maternal and fetal outcomes when initiated within the first trimester of pregnancy in GDM. A retrospective analysis of 540 women with diabetes complicating pregnancy (IADPSG criteria) over five years (January 2011 to May 2016) was done. The study population comprised of patients initiated on (a) metformin within the first trimester (Group A:n = 186), (b) metformin after the first trimester (Group B:n = 203) and (c) insulin at any time during their pregnancy (Group C:n = 151). The primary outcomes compared were prematurity, respiratory distress, birth trauma, 5-min APGAR score, neonatal hypoglycaemia and need for phototherapy, while secondary outcomes compared were neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance. Individual and composite primary or secondary outcomes in group A were similar to Groups B and C, though numerically higher premature births were seen in Group A. There was a 1.3% overall incidence of stillbirths/IUD, while 1.11% congenital anomalies were noted of which 2.15% were in group A and 1.32% were in Group C (p = .16). The initiation of metformin within the first trimester of pregnancy has no significant adverse maternal or fetal outcomes. However, vigilance for premature births is recommended in women exposed to metformin in early pregnancy.